US20140039043A1 - Pharmaceutical compositions comprising cannabigerol - Google Patents

Pharmaceutical compositions comprising cannabigerol Download PDF

Info

Publication number
US20140039043A1
US20140039043A1 US13/869,247 US201313869247A US2014039043A1 US 20140039043 A1 US20140039043 A1 US 20140039043A1 US 201313869247 A US201313869247 A US 201313869247A US 2014039043 A1 US2014039043 A1 US 2014039043A1
Authority
US
United States
Prior art keywords
cannabigerol
derivative
type compound
cannabis plant
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/869,247
Inventor
Richard Musty
Richard Deyo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US81381406P priority Critical
Priority to US11/760,364 priority patent/US8481085B2/en
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Priority to US13/869,247 priority patent/US20140039043A1/en
Assigned to GW PHARMA LIMITED reassignment GW PHARMA LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DEYO, RICHARD, MUSTY, RICHARD
Publication of US20140039043A1 publication Critical patent/US20140039043A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.

Description

    RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 11/760,364, filed Jun. 8, 2007, which application claims the benefit under 35 U.S.C. §119(e) of U.S. provisional application 60/813,814, filed Jun. 15, 2006, the entire disclosures of which are incorporated herein by reference.
    • FIELD OF THE INVENTION
  • The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.
    • BACKGROUND OF THE INVENTION
  • Mood disorders are generally classified by type and include, but are not limited to:
  • A morbid or clinical depression, which is usually diagnosed when sadness or elation is overly intense and continues beyond the expected impact of an event. Symptoms often recur on an episodic basis or pursue a low-grade intermittent chronicity, which impairs the functioning of the sufferer.
  • Bipolar mood disorder, which commonly begins with depression and is characterised by periods of elation during the course of the illness.
  • Unipolar mood disorder, which is characterised as syndromal depression of episodes that last for typically 6 to 9 months.
  • The pharmaceuticals used in the treatment of Bipolar mood disorders can be grouped into three classes; the heterocyclic antidepressants (HCAs), monoamine oxidase inhibitors (MAOIs) and lithium salts.
  • HCAs are the largest class of antidepressants and include tricyclic antidepressants such as imipramine. The HCAs have no immediate effect on euphoria and therefore have a low abuse potential. This group of antidepressants work by increasing the availability of the biogenic amines norepinephrine and/or serotonin (5-HT) by blocking reuptake in the synaptic cleft. The side effects of HCAs include tachycardia, postural hypotension and cardio-toxicity. HCAs are also commonly associated with blurred vision, xerostomia, constipation, urinary hesitation, sedation and weight gain. The hypotensive side effects of HCAs often make them unsuitable for patients with mental disorders and the elderly.
  • MAOIs such as phenelzine are often prescribed for panic disorders. They work by the inhibition of the oxidative deamination of the 3 classes of biogenic amines; noradrenergic, dopaminergic and 5-HT. MAOIs are underused because of clinician's fears of hypertension that may result from dietary or drug reactions, popularly known as the ‘cheese reaction’ due to the high tyramine content in cheeses and other foods. Other common side effects of MAOIs include erectile difficulties, anxiety, nausea, dizziness, insomnia, edema and weight gain.
  • Lithium is used to stabilise the often unpredictable mood swings in bipolar mood disorder. The precise mechanism of action is unknown, but it is postulated that it is able to cause hyperpolarisation of the neuronal membrane. The most common acute benign side effects are tremour, fasciculation, nausea, diarrhoea, polyuria, polydipsia and weight gain. Lithium toxicity is more likely in elderly patients.
  • The applicants have previously shown that the cannabinoid cannabichromene is useful in the treatment of mood disorders as described in the International patent application WO2005/000830. However the actions of many cannabinoids such as THC are linked with an increase in mood disorders in users.
    • SUMMARY OF THE INVENTION
  • Surprisingly the applicants have found that cannabigerol (CBG) and cannabigerol type compounds (including cannabigerol propyl analogue (CBGV)) and derivatives thereof, are useful in the treatment of mood disorders, particularly depression.
  • The naturally occurring cannabinoid CBG is a precursor to the major cannabinoids CBD, CBC and THC and as such is rarely found in cannabis plants in any significant concentration. As such this cannabinoid was not thought to possess pharmacological properties.
  • According to the first aspect of the present invention there is provided a method of treating a mood disorder in a human patient which comprises administering to a patient in need thereof a therapeutically effective amount of at least one cannabigerol type compound or derivative.
  • Preferably the mood disorder to be treated is one or more of the following; morbid or clinical depression; unipolar mood disorder; bipolar mood disorder; syndromal depression; panic disorder and anxiety.
  • Preferably the mood disorder to be treated is depression.
  • References to CBG, CBG type compounds or derivatives thereof, particularly with regard to therapeutic use, will be understood to also encompass pharmaceutically acceptable salts of such compounds. The term “pharmaceutically acceptable salts” refers to salts or esters prepared from pharmaceutically acceptable non-toxic bases or acids, including inorganic bases or acids and organic bases or acids, as would be well known to persons skilled in the art. Many suitable inorganic and organic bases are known in the art.
  • Cannabinoid biosynthesis begins when a precursor molecule reacts with geranylpyrophosphate to form a ringed structure. As shown in FIG. 1, CBG type compounds are mostly 21 carbon compounds.
  • Variation in the length of the side chain that is attached to the aromatic ring (bottom right hand side of the structure) can produce different types of CBG compounds. For example when the side chain is a pentyl (5 carbon) chain the compound produced will be CBG. If the pentyl chain is replaced with a propyl (3 carbon) chain the CBD type compound formed is CBGV (cannabigeroldivarin). The propyl variant will be formed if a 10 carbon precursor is reacted at the first stage of the biosynthetic pathway rather than a 12 carbon compound.
  • Synthetic variants of CBG include dimethylheptyl CBG. This variant also has variations in the side chain of the CBG compound.
  • The scope of the invention also extends to derivatives of CBG that retain the desired activity of being useful in the treatment of mood disorders. Derivatives that retain substantially the same activity as the starting material, or more preferably exhibit improved activity, may be produced according to standard principles of medicinal chemistry, which are well known in the art. Such derivatives may exhibit a lesser degree of activity than the starting material, so long as they retain sufficient activity to be therapeutically effective. Derivatives may exhibit improvements in other properties that are desirable in pharmaceutical active agents such as, for example, improved solubility, reduced toxicity, enhanced uptake, etc.
  • Preferably the at least one cannabigerol type compound or derivative thereof is an extract from a cannabis plant.
  • The term “cannabis plant/s” encompasses wild type Cannabis sativa and also variants thereof, including cannabis chemovars (varieties characterised by virtue of their chemical composition) which naturally contain different amounts of the individual cannabinoids, also Cannabis sativa subspecies indica including the variants var. indica and var. kafiristanica, Cannabis indica and also plants which are the result of genetic crosses, self-crosses or hybrids thereof. The term “cannabis plant material” is to be interpreted accordingly as encompassing plant material to be derived from one or more cannabis plants. For the avoidance of doubt it is hereby stated that cannabis plant material includes herbal cannabis and dried cannabis biomass.
  • More preferably the extract from the cannabis plant comprises all of the naturally occurring cannabinoids and other non-cannabinoid components that are co-extracted with the at least one cannabigerol type compound or derivative thereof.
  • An extract from a cannabis plant contains in addition to one or more cannabinoids, one or more non-cannabinoid components which are co-extracted with the cannabinoids from the plant material. Their respective ranges will vary according to the starting plant material and the extraction methodology used. Cannabis plant extracts may be obtained by various means of extraction of cannabis plant material. Such means include but are not limited to: supercritical or subcritical extraction with CO2, extraction with hot gas and extraction with solvents.
  • In one embodiment the extract from the cannabis plant may be enriched for cannabigerol. In other words the extract contains a greater proportion of the total cannabinoid content as cannabigerol as compared to the cannabinoid composition from which the extract was prepared.
  • This enrichment may be achieved by selecting a fraction of the initial plant extract or by purifying the plant extract further after extraction to select specifically for cannabigerol.
  • Preferably the cannabis plant extract included in the pharmaceutical formulation of the invention will contain greater than or equal to 80% (w/w) cannabigerol of the total cannabinoid content, more preferably greater than or equal to 90%, more preferably greater than or equal to 95%, more preferably still greater than or equal to 99%.
  • In a further embodiment the at least one cannabigerol type compound or derivative thereof is isolated or substantially pure.
  • Isolated or substantially pure cannabigerols will be substantially free of other cannabinoids and other non-cannabinoid components such as terpenes. The isolated or substantially pure cannabigerols may be of natural i.e. plant origin or they may be synthetically produced compounds.
  • The process disclosed in the applicants granted United Kingdom patent GB2393721 describes a process for preparing substantially pure CBG.
  • “Substantially pure” is defined herein as preparations of cannabigerol type compounds or derivatives thereof having a chromatographic purity of greater than 95%, preferably greater than 96%, more preferably greater than 97%, more preferably greater than 98%, more preferably greater than 99% and most preferably greater than 99.5%, as determined by area normalisation of an HPLC profile.
  • The pharmaceutical formulation of the invention may be formulated for delivery nasally, sublingually, buccally, topically, orally, rectally, intravenously, intra-peritoneally, intra-muscularly, subcutaneously, transdermally, intra-vaginally, intra-urethrally, by nebuliser, as inhaled vapour or by instillation into the bladder.
  • The formulation may be in liquid or solid dosage form and may include in addition to the active, other pharmaceutically acceptable components such as excipients, solvents, diluents, fillers, salts, buffers, stabilisers, solubilisers etc. The dosage form may contain other pharmaceutically acceptable excipients for modifying conditions such as pH, osmolarity, taste, viscosity, sterility, lipophilicity, solubility etc. The choice of diluents, carriers or excipients will depend on the dosage form, which may in turn be dependent on the route of administration.
  • Solid dosage forms include for example, tablets, capsules, powders, dispersible granules, cachets and suppositories, including sustained release and delayed release formulations.
  • Liquid dosage forms include solutions, suspensions and emulsions.
  • Aerosol preparations suitable for inhalation may include solutions and solids in a powder form, which may be combined with a pharmaceutically acceptable carrier, such as an inert compressed gas.
  • Also encompassed are dosage forms for transdermal administration including creams, lotions, aerosols and or emulsions.
  • Pharmaceutical preparations may be conveniently prepared in a unit dosage form according to standard procedures of pharmaceutical formulation. The quantity of active compound per dosage form may be varied according to the nature of the active and the intended dosage regime. Generally this will be with in the range of 0.1 to 1000 mg.
  • In a second aspect of the present invention there is provided a method of treating a mood disorder in a human patient which comprises administering to a patient in need thereof a therapeutically effective amount of at least one cannabigerol type compound or derivative, wherein the pharmaceutical formulation further comprises one or more additional cannabinoids.
  • Preferably the one or more additional cannabinoid is cannabidiol (CBD).
  • Alternatively the one or more additional cannabinoid is cannabichromene (CBC).
    • DETAILED DESCRIPTION OF THE INVENTION
  • There are over sixty identified cannabinoids that are known to be produced the by cannabis plant. Of these cannabinoids there are eight different main classes of cannabinoids: cannabigerol-type; cannabichromene-type; cannabidiol-type; tetrahydrocannabinol-type; cannabielsoin-type; iso-tetrahydrocannabinol-type; cannabicyclol-type; and cannabicitran-type.
  • All of these main classes of cannabinoids are derived from cannabigerol-type compounds and differ mainly in the way the CBG precursor is cyclised.
  • The structure of cannabigerol is shown in FIG. 1 and the biosynthetic pathway is detailed in FIG. 2. Cannabinoid production in cannabis plants begins when an enzyme causes geranyl pyrophosphate and olivetolic acid to condense to form cannabigerol. The CBG cannabinoid is then usually converted by cannabinoid synthase enzymes to cannabidiol (CBD), cannabichromene (CBC) or tetrahydrocannabinol (THC).
  • Due to the nature of the biosynthetic pathway of cannabinoids most cannabis plants do not comprise a large amount of CBG. As such the pharmacology of CBG is largely unknown and it has been postulated that CBG is merely a precursor to other more pharmacologically active cannabinoids. The inventors postulated that it is possible, due to the biosynthetic pathway of the cannabinoids, that CBG will share some common properties with its products such as CBD and CBC. Also it is conceivable that the combination of CBG with its products such as CBC, CBD and THC will produce a greater and more beneficial effect than that produced by CBG alone.
  • It was shown by Elsohly et al. in 1992 that CBG had antimicrobial properties and more recently in 2005 Maor et al. described a synthetic analogue of CBG, CBG-dimethyl heptyl which possessed hypotensive and vasorelaxant properties. Compared with the vast knowledge available on THC or CBD, CBG's properties are relatively unknown.
  • Some patients have found cannabis to be useful in the treatment of anxiety, depression and bipolar mood disorders (Zimmerman, 1998). However reports on the therapeutic potential of cannabis are often contradictory as they describe the effects of whole, usually smoked cannabis, rather than the actions of the specific cannabinoids themselves. Indeed THC is often associated with anxiety and mood disorders, particularly in recreational users.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • Certain aspects of this invention are further described, by way of example only, with reference to the accompanying drawings in which:
  • FIG. 1 shows the structure of cannabigerol; and
  • FIG. 2 shows the biosynthetic pathway of the major cannabinoids.
    •
  • The present invention is further illustrated by the following Example, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications) cited throughout this application are hereby expressly incorporated by reference for the purpose cited herein.
    • EXAMPLE 1 Alteration of Behavioural Despair in an Animal Model of Depression
  • A substantially pure extract of cannabigerol, purified from a cannabis plant extract, was tested for its ability to modify the behaviour of mice during an open field test and a tail suspension test (Steru et al., 1985, Psychopharmacology (Berl.) 85(3), 367-370). The CBG extract was compared to a known antidepressant imipramine.
  • The experiment used groups of 7-8 C57 B16J mice and these were tested with doses of 0, 5, 10, 20, 40, 60 and 80 mg/kg ip of CBG extract. The dose of imipramine that was used was the standard dose that is known to produce an anti-depressant effect of 30 mg/kg ip. One group of animals were administered a vehicle control.
  • The open field apparatus consisted of a 44.5×44.5×30 cm chamber with clear plastic walls and a white plastic floor. Behaviours were recorded using a Quasar video recorder suspended above the chamber. The chamber was divided into four equal sized quadrants during scoring by placing a clear plastic template on the video screen. Behaviours were scored using data collection software.
  • The animals were subjected to a tail suspension test whereby a sound-attenuated chamber with a titanium bar mounted 15 cm from the floor was used. An opto-electronic sensor was mounted in a white plastic column and positioned from the mounting bar. An infra-red light transmitted from an LED onto the animal. If the animal moved, the amount of light collected by the phototransistor would increase or decrease depending on the size of the movement.
  • On the day of testing the mice were weighed and randomly assigned to a group prior to test article or control drug being injected intraperitoneally. Thirty minutes later each mouse was tested on the tail suspension test for six minutes.
  • The mouse was suspended from a bar by the tip of its tail using adhesive tape so that the tip of their nose was 2 cm from the floor of the chamber. The total number of movements and total amount of time spent immobile were recorded.
  • Immediately after the tail suspension test the mouse was placed individually in the open-field chamber for five minutes. The frequency of crossings, rears, grooming and defecation were recorded for each subject.
    • Results:
  • Antidepressant effects are indicated by an increase in the frequency of struggling activity during the test. In addition the degree or amplitude of struggling is thought to be a predictor of antidepressant activity.
  • At a dose of CBG greater than or equal to 40 mg/kg the amount of struggling was significantly increased compared with the animals administered the vehicle control. This dose of CBG gave similar responses as the standard dose of imipramine.
    • CONCLUSION
  • The data presented suggest that CBG may induce antidepressant effects. Moderate doses of CBG produced behaviours that were consistent to imipramine in the tail suspension test and as such the use of this naturally occurring cannabinoid may have beneficial effects over that of HCA antidepressants such as imipramine which are known to cause many side effects in users.

Claims (22)

1. A method of treating a mood disorder in a human patient which comprises administering to a patient in need thereof a therapeutically effective amount of at least one cannabigerol type compound or derivative.
2. The method as claimed in claim 1, wherein the mood disorder to be treated is one or more of the following; morbid or clinical depression; unipolar mood disorder; bipolar mood disorder; syndromal depression; panic disorder and anxiety.
3. The method as claimed in claim 2, wherein the mood disorder to be treated is depression.
4. The method as claimed in claim 1, wherein the at least one cannabigerol type compound or derivative thereof is an extract from a cannabis plant.
5. The method as claimed in claim 4, wherein the extract from the cannabis plant comprises all of the naturally occurring cannabinoids and other non-cannabinoid components that are co-extracted with the at least one cannabigerol type compound or derivative thereof.
6. The method as claimed in claim 4, wherein the extract from the cannabis plant is enriched for cannabigerol.
7. The method as claimed in claim 1, wherein the cannabis plant extract contains a greater than or equal to 80% (w/w) cannabigerol of the total cannabinoid content.
8. The method as claimed in claim 7, wherein the cannabis plant extract contains greater than or equal to 90% (w/w) cannabigerol of the total cannabinoid content.
9. The method as claimed in claim 8, wherein the cannabis plant extract contains greater than or equal to 95% w/w) cannabigerol of the total cannabinoid content.
10. The method as claimed in claim 9, wherein the cannabis plant extract contains greater than or equal to 99% (w/w) cannabigerol of the total cannabinoid content.
11. The method as claimed in claim 1, wherein the at least one cannabigerol type compound or derivative thereof is isolated or substantially pure.
12. The method as claimed in claim 1, wherein the pharmaceutical formulation is formulated for delivery nasally, sublingually, buccally, topically, orally, rectally, intravenously, intra-peritoneally, intra-muscularly, subcutaneously, transdermally, intra-vaginally, intra-urethrally, by nebuliser, as inhaled vapour or by instillation into the bladder.
13. The method as claimed in claim 1, wherein a unit dosage form comprises at least one cannabigerol type compound or derivative thereof in an amount of 0.1 to 1000 mg.
14. A method of treating a mood disorder in a human patient which comprises administering to a patient in need thereof a therapeutically effective amount of at least one cannabigerol type compound or derivative, wherein the pharmaceutical formulation further comprises one or more additional cannabinoids.
15. The method as claimed in claim 14, wherein the one or more additional cannabinoids is cannabidiol (CBD).
16. The method as claimed in claim 14, wherein the one or more additional cannabinoids in cannabichromene (CBC).
17. The method as claimed in claim 1, wherein the at least one cannabigerol type compound or derivative is cannabigerol (CBG).
18. The method as claimed in claim 1, wherein the at least one cannabigerol type compound or derivative is cannabigerol propyl analogue (CBGV).
19. The method as claimed in claim 1, wherein the at least one cannabigerol type compound or derivative is cannabigerol-dimethyl heptyl.
20. The method as claimed in claim 14, wherein the at least one cannabigerol type compound or derivative is cannabigerol (CBG).
21. The method as claimed in claim 14, wherein the at least one cannabigerol type compound or derivative is cannabigerol propyl analogue (CBGV).
22. The method as claimed in claim 14, wherein the at least one cannabigerol type compound or derivative is cannabigerol-dimethyl heptyl.
US13/869,247 2006-06-15 2013-04-24 Pharmaceutical compositions comprising cannabigerol Abandoned US20140039043A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US81381406P true 2006-06-15 2006-06-15
US11/760,364 US8481085B2 (en) 2006-06-15 2007-06-08 Pharmaceutical compositions comprising cannabigerol
US13/869,247 US20140039043A1 (en) 2006-06-15 2013-04-24 Pharmaceutical compositions comprising cannabigerol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/869,247 US20140039043A1 (en) 2006-06-15 2013-04-24 Pharmaceutical compositions comprising cannabigerol

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/760,364 Continuation US8481085B2 (en) 2006-06-15 2007-06-08 Pharmaceutical compositions comprising cannabigerol

Publications (1)

Publication Number Publication Date
US20140039043A1 true US20140039043A1 (en) 2014-02-06

Family

ID=38353631

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/760,364 Active US8481085B2 (en) 2006-06-15 2007-06-08 Pharmaceutical compositions comprising cannabigerol
US13/869,247 Abandoned US20140039043A1 (en) 2006-06-15 2013-04-24 Pharmaceutical compositions comprising cannabigerol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/760,364 Active US8481085B2 (en) 2006-06-15 2007-06-08 Pharmaceutical compositions comprising cannabigerol

Country Status (5)

Country Link
US (2) US8481085B2 (en)
EP (1) EP2037901B1 (en)
JP (1) JP5286255B2 (en)
CA (1) CA2655094C (en)
WO (1) WO2007144628A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000830A1 (en) * 2003-06-24 2005-01-06 Gw Pharma Limited Pharmaceutical compositions comprising cabbinochreme type compounds
GB2450493A (en) * 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US20100293021A1 (en) * 2009-01-23 2010-11-18 Intranet Productivity Solutions, Ltd. Method and system for task tracking and allocation
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
US10045540B2 (en) 2014-04-01 2018-08-14 Fayetteville State University Pest control composition
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
WO2018000094A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
JP2020505417A (en) 2017-02-01 2020-02-20 ジービーエス グローバル バイオファーマ，インコーポレイテッド Complex mixtures containing cannabinoids for the treatment of mast cell-related inflammatory disorders or basophil-mediated inflammatory disorders
US10272360B2 (en) 2017-08-05 2019-04-30 Priya Naturals, Inc. Phytochemical extraction system and methods to extract phytochemicals from plants including plants of the family Cannabaceae sensu stricto
US20200405685A1 (en) * 2017-12-08 2020-12-31 Biotech Institute, Llc High cannabigerol cannabis plants, methods of producing and methods of using them
US20190231737A1 (en) * 2018-01-31 2019-08-01 Canopy Holdings, LLC Hemp powder
WO2020092823A1 (en) * 2018-10-31 2020-05-07 Baymedica, Inc. Cannabinoid analogs and methods for their preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020117175A1 (en) * 2000-10-27 2002-08-29 Kottayil S. George Thermal vaporizing device for drug delivery
US20040034108A1 (en) * 2002-08-14 2004-02-19 Brian Whittle Pharmaceutical formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2381450B (en) 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
WO2003101357A1 (en) * 2002-05-31 2003-12-11 University Of Mississippi Transmucosal delivery of cannabinoids
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
WO2005000830A1 (en) 2003-06-24 2005-01-06 Gw Pharma Limited Pharmaceutical compositions comprising cabbinochreme type compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020117175A1 (en) * 2000-10-27 2002-08-29 Kottayil S. George Thermal vaporizing device for drug delivery
US20040034108A1 (en) * 2002-08-14 2004-02-19 Brian Whittle Pharmaceutical formulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hysteria is a Normal Effect of Anxiety, 8 pages, 2016. *
Merrium Webster, 11 pages, 2017. *
Schizophrenia: Symptoms, Types, Causes, and Early Warning Signs, 7 pages, 2016. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use

Also Published As

Publication number Publication date
US20080031977A1 (en) 2008-02-07
EP2037901A1 (en) 2009-03-25
US8481085B2 (en) 2013-07-09
WO2007144628A1 (en) 2007-12-21
JP5286255B2 (en) 2013-09-11
CA2655094A1 (en) 2007-12-21
EP2037901B1 (en) 2014-01-08
JP2009539961A (en) 2009-11-19
CA2655094C (en) 2014-09-30

Similar Documents

Publication Publication Date Title
US20190000867A1 (en) Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
Rezaee et al. Safranal: from an aromatic natural product to a rewarding pharmacological agent
US20190224140A1 (en) Cannabinoids for use in the treatment of neuropathic pain
TWI577373B (en) A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd)
Gottlieb et al. Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia
Ojemann et al. Tian ma, an ancient Chinese herb, offers new options for the treatment of epilepsy and other conditions
US20200206151A1 (en) Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
EP1019044B1 (en) Composition and methods for treating alzheimer's disease and other amyloidoses
ES2746973T3 (en) Plant extracts containing cannabinoids as neuroprotective agents
EP1556021B1 (en) Pharmaceutical compositions comprising flavonoids and menthol
Chonpathompikunlert et al. Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer’s disease
US20130245111A1 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
US9730911B2 (en) Cannabis extracts and methods of preparing and using same
CN103179962B (en) Use of malononitrilamides in neuropathic pain
US8354447B2 (en) mGLU receptors antagonists for treating disorders associated with mGLU receptors including addiction and depression
Souza et al. Evidence for the involvement of the serotonergic 5-HT1A receptors in the antidepressant-like effect caused by hesperidin in mice
Meltzer Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies
US20190151398A1 (en) Pharmaceutical Composition Comprising Cannabidiol (CBD) and Lecithin
US8440704B2 (en) Quercetin-containing compositions
Munoz-Torrero Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease
Mechoulam et al. Towards cannabinoid drugs-revisited
Costa On the pharmacological properties of Δ9‐tetrahydrocannabinol (THC)
Hussain et al. Phytopharmacological potential of different species of Morus alba and their bioactive phytochemicals: A review
US9101649B2 (en) Phenolic compositions derived from apple skin and uses thereof
TWI402069B (en) Quercetin-containing compositions

Legal Events

Date Code Title Description
AS Assignment

Owner name: GW PHARMA LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUSTY, RICHARD;DEYO, RICHARD;SIGNING DATES FROM 20070913 TO 20070914;REEL/FRAME:030764/0338

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION